Avecho Biotechnology Limited has announced a collaboration with Lambert Initiative ("the Lambert") at the University of Sydney to conduct a proof of concept study to examine whether topically applied cannabidiol ("CBD") can provide relief from symptoms of osteoarthritis. The Phase IIa Study (the "Study") is being run by Principal Investigator, Dr. Daniel Lewis, from the Daniel Lewis Rheumatology Centre and Co-Investigator, Professor Iain McGregor, from the Lambert. The study has been initiated in response to growing demand from patients who are unsatisfied with their level of pain management provided by current treatments for osteoarthritis of the hand. About half of all women and one-quarter of all men1 will experience osteoarthritis ("OA") of the hand by the time they are 85 years old. OA causes the protective cartilage on the ends of bones to break down and wear away. Over time, bones rub together, causing stiffness and pain. It is a chronic and debilitating disease with limited treatment options available. CBD is a non-intoxicating compound derived from cannabis that has been approved for the management of paediatric epilepsies2 and is being prescribed through the TGA's special access schemes for conditions like chronic pain, neuropathic pain and fibromyalgia3. CBD has analgesic and anti-inflammatory properties, making it a desirable candidate for osteoarthritis management. The Study uses one of Avecho's proprietary formulation vehicles incorporating its TPM? technology. This formulation has already been shown to increase the dermal absorption of CBD in laboratory experiments by five times. Approximately 20 patients suffering painful arthritis of the fingers or thumb will be enrolled. They will be asked to apply the topical formulation to their painful joints each day over a four week period. Assessment will include pain scores, functional scores, and grip strength using innovative technologies, including a dynamometer and a smartphone app.